Cancer News and Research

Latest Cancer News and Research

Noninvasive method to determine estrogen levels in infants through diapers

With the help of babies and more than 5,000 of their diapers, Emory University researchers have developed an accurate, noninvasive method to determine estrogen levels in infants.

17 Nov 2010

New OncoMap technique can detect point mutation in ovarian cancer

Researchers have shown that point mutations mis-spellings in a single letter of genetic code that drive the onset and growth of cancer cells can be detected successfully in advanced ovarian cancer using a technique called OncoMap. The finding opens the way for personalised medicine in which every patient could have their tumour screened, specific mutations identified, and the appropriate drug chosen to target the mutation and halt the growth of their cancer.

17 Nov 2010

John Muir Health opens The Hofmann Family Patient Care Tower

Today, John Muir Health opened the doors of The Hofmann Family Patient Care Tower at John Muir Medical Center, Concord, which includes 120 new private rooms (61 open with 59 shelled for future use), a new Cardiovascular Institute and a new Emergency Department. The 172,000 square foot facility, which took three years and $212 million to complete, also features state-of-the-art technology and a patient-focused, healing environment.

17 Nov 2010

Combination doxorubicin-sorafenib treatment improves survival in patients with inoperable advanced liver cancer

Treatment of inoperable advanced liver cancer with the agent doxorubicin (routinely used to treat this condition) in addition to the agent sorafenib resulted in greater overall survival and progression-free survival, compared to patients who received treatment with doxorubicin alone, according to a study in the November 17 issue of JAMA.

17 Nov 2010

Enzon presents data on three investigational mRNA antagonists at EORTC-NCI-AACR Symposium

Enzon Pharmaceuticals, Inc. today presented data from preclinical studies of three investigational messenger RNA (mRNA) antagonists. These antagonists are based on the locked nucleic acid (LNA) technology platform targets licensed from Santaris Pharma A/S.

17 Nov 2010

Chimerix’s lipid-conjugated drugs reduces nephrotoxicity: Study

Scientists from Chimerix, Inc. today presented in vitro data demonstrating that the company's lipid-conjugated drugs, CMX001 and CMX157, are not substrates for the human Organic Anion Transporters (hOATs) and thus have significantly reduced potential to cause nephrotoxicity via this mechanism.

17 Nov 2010

MRL announces acquisition of world's largest cryo-preserved human cancer tissue bank

Molecular Response (MRL), a privately held molecular diagnostic services company and a leader in the identification of target populations for high value therapeutics, announced today the acquisition of the world's largest cryo-preserved human cancer tissue bank—more than 144,000 specimens procured over 20 years. The company acquired the tumor bank, along with properly de-identified clinical information and validated test procedures, as part of a major acquisition of key assets formerly owned by Oncotech.

17 Nov 2010

Maine has most improved health care quality; Kansas needs more dentists

Maine Public Broadcasting Network News: "Nationwide, Maine is most improved when it comes to health care quality, according to 2009 statistics from the federal Agency for Healthcare Research and Quality. In one year, Maine jumped from 12th place to fourth best in categories ranging from cancer to patient safety, from maternal and child health to long-term care.

17 Nov 2010

Medicare roundup: Payment cuts irk healthcare industry; officials mull new prostate-cancer treatment

Doctors across the United States are taking a wait-and-see approach while Congress decides whether or not to allow a scheduled 23% cut in Medicare reimbursement rates to take effect on Dec. 1.

17 Nov 2010

Study: EGFR inhibtion may help treat triple negative breast cancer

Scientists believe they may have found a new target for treating triple negative breast cancer - one of the more difficult breast cancers to treat successfully and for which there is no targeted therapy at present.

17 Nov 2010

AVEO commences enrollment in Phase 1b combination trial of tivozanib with oral capecitabine in advanced tumors

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated patient enrollment in an open-label, multi-center Phase 1b clinical trial evaluating tivozanib in combination with oral capecitabine (Xeloda®) in patients with certain advanced solid tumors.

17 Nov 2010

Progenics initiates ONO-3849 phase 2 clinical trial for OIC in Japan

Progenics Pharmaceuticals, Inc. today announced the initiation of a phase 2 clinical trial of subcutaneous methylnaltrexone in Japan by its collaborator, Ono Pharmaceutical Co., Ltd. The drug, designated ONO-3849 in Japan, is being evaluated for the treatment of opioid-induced constipation (OIC) in patients with advanced illness such as cancer.

17 Nov 2010

Tengion permits second patient enrollment in Neo-Urinary Conduit for bladder cancer

Tengion, Inc., a leader in regenerative medicine, announced today that the scheduled one-month, post-operative clinical assessment of the first implanted bladder cancer patient in its ongoing clinical trial has been completed as expected and has permitted the second patient to be enrolled without delay.

16 Nov 2010

Isis, Xenon enter collaboration to discover and develop antisense drugs for AI

Isis Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc. announced today a new collaboration to discover and develop antisense drugs as novel treatments for the common disease anemia of inflammation (AI).

16 Nov 2010

Verastem closes $16 million Series A financing

Verastem, Inc., a biopharmaceutical company focused on discovering and developing drugs to treat cancer by targeting cancer stem cells, today announced the closing of a $16 million Series A financing. Founding investor, Longwood Founders Fund, was joined by Bessemer Venture Partners, Cardinal Partners, and MPM Capital.

16 Nov 2010

Today's Op-Eds: Congress needs conservative leadership; reviving tort reform; can states afford to drop Medicaid?

Nothing has gone quite so awry as the massive, government-run Obama health program, and it is plain that the individual mandate, the employee mandate, the abortion funding, the tangle of outsider/insider councils like the comparative effectiveness board and the effective nationalization of healthcare under grants of authority to the Department of Health and Human Services.

16 Nov 2010

Risk reduction of 20 ailments with regular exercise: Review

In a review article researchers have concluded that regular exercise cuts the risk of more than 20 illnesses. Some of these include colon cancer, heart disease, diabetes, osteoporosis and stroke said the study published in the International Journal of Clinical Practice.

16 Nov 2010

Urgent need for bowel cancer screening funding

Bowel Cancer Foundation chairman, Graham Newstead feeling frustrated at the federal government’s indecision on bowel cancer screening funds has expressed his dismay. He suggested that the government should ensure the future funding for the screening test that has saved an estimated 11,000 lives since screening was introduced in 2006.

16 Nov 2010

Patrys announces capital raising of $3.2 million and share purchase plan

Patrys Limited (ASX: PAB; Company), a biotechnology company focused on the development of revolutionary new treatments for cancer, is pleased to announce a successful capital raising of approximately $3.2 million, which was conducted via a private placement.

16 Nov 2010

BUSM professor wins 2010 Maurice Wood Award for Lifetime Contribution to Primary Care Research

Larry Culpepper, MD, MPH, chair and professor of family medicine at Boston University School of Medicine (BUSM) and chief of family medicine at Boston Medical Center (BMC), is the recipient of the 2010 Maurice Wood Award for Lifetime Contribution to Primary Care Research.

16 Nov 2010

Cancer News and Research

Latest Cancer News and Research

Noninvasive method to determine estrogen levels in infants through diapers

New OncoMap technique can detect point mutation in ovarian cancer

John Muir Health opens The Hofmann Family Patient Care Tower

Combination doxorubicin-sorafenib treatment improves survival in patients with inoperable advanced liver cancer

Enzon presents data on three investigational mRNA antagonists at EORTC-NCI-AACR Symposium

Chimerix’s lipid-conjugated drugs reduces nephrotoxicity: Study

MRL announces acquisition of world's largest cryo-preserved human cancer tissue bank

Maine has most improved health care quality; Kansas needs more dentists

Medicare roundup: Payment cuts irk healthcare industry; officials mull new prostate-cancer treatment

Study: EGFR inhibtion may help treat triple negative breast cancer

AVEO commences enrollment in Phase 1b combination trial of tivozanib with oral capecitabine in advanced tumors

Progenics initiates ONO-3849 phase 2 clinical trial for OIC in Japan

Tengion permits second patient enrollment in Neo-Urinary Conduit for bladder cancer

Isis, Xenon enter collaboration to discover and develop antisense drugs for AI

Verastem closes $16 million Series A financing

Today's Op-Eds: Congress needs conservative leadership; reviving tort reform; can states afford to drop Medicaid?

Risk reduction of 20 ailments with regular exercise: Review

Urgent need for bowel cancer screening funding

Patrys announces capital raising of $3.2 million and share purchase plan

BUSM professor wins 2010 Maurice Wood Award for Lifetime Contribution to Primary Care Research

Cancer Research - Second Edition eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in